世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

欧米医薬品製造市場の規模、シェア、動向分析レポート 製品タイプ別、タイプ別、医薬品開発タイプ別、製剤別、投与経路別、セグメント別予測、2023年~2030年


U.S. And Europe Pharmaceutical Manufacturing Market Size, Share & Trends Analysis Report By Product Type, By Type, By Drug Development Type, By Formulation, By Routes of Administration, And Segment Forecasts, 2023 - 2030

米国・欧州医薬品製造市場の成長とトレンド Grand View Research, Inc.の新しいレポートによると、米国と欧州の医薬品製造市場規模は2030年までに6412億2000万米ドルに達し、2023年から2030年まで6.81%のCAGR... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年1月19日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報・注文方法はこちら
150 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

米国・欧州医薬品製造市場の成長とトレンド

Grand View Research, Inc.の新しいレポートによると、米国と欧州の医薬品製造市場規模は2030年までに6412億2000万米ドルに達し、2023年から2030年まで6.81%のCAGRで拡大すると予測されています。支持的な規制法の存在、特許性規範、製薬業界への高い投資、医療費の増加は、依然として成長の主要な推進要因となっています。また、製薬業界における第三者生産の傾向の高まりや、コスト削減への取り組みの重視は、有利な成長機会をもたらすと考えられます。

医薬品の臨床試験件数の継続的な増加は、今後数年間、市場成長のための数多くの機会を生み出すと期待されています。ClinicalTrials.govによると、2023年1月現在、米国では合計137,145件の進行中の臨床試験が登録されており、これは臨床試験全体の31%を占めている。このような臨床試験数の増加は、製薬業界の成長を示しており、市場関係者に新たな道を切り開くものと思われます。

さらに、医薬品メーカーの大半は、医薬品不足を克服し、製造コストを削減し、製造効率を向上させるために、連続生産方式を選択するようになりました。例えば、2021年1月、CONTINUUS Pharmaceuticals Inc.は、重症患者を治療するための3つの必須医薬品の国レベルでの生産を加速させるための6930万米ドルの米国政府契約の受領を発表しました。さらに、この契約により、同社はコスト効率の高い生産を可能にし、高品質で手頃な価格の治療薬を患者に提供することを促進しました。

国内の医薬品製造拠点を設立するための政府のイニシアチブは、医薬品製造市場の成長を決定する要因の1つです。例えば、2022年4月、CureVacとGSK plcは、mRNAの生産能力を高めるためにドイツのパンデミック危機管理計画の一部となるパートナーシップを締結し、政府は2029年までCureVacの生産能力へのアクセスを受けることになります。

英国政府は、Medicines Manufacturing Innovation Centreを通じて、現地生産の確立に向けた取り組みを進めています。このプログラムでは、医薬品メーカー、学術機関、医療提供者、規制機関が、この施設でそれぞれのリソースを結集し、自律的な生産を含む新しい技術のテストと強化を行うことが期待されています。

さらに、製薬会社が事業の道筋を強化するために行う有機的・無機的な開発は、市場の拡大をサポートすると予想されます。例えば、2021年10月、Samsung BiologicsとEnzolytics, Inc.は、抗SARS-CoV-2モノクローナル抗体と抗HIV療法の開発&製造契約を締結した。同様に、2021年2月、WuXi STAはスイスにあるBristol Myers Squibbの製造部門を買収しました。この拡張により、既存の能力がさらに強化されます。

米国および欧州の医薬品製造市場ハイライト

- 低分子の消費率の高さと製品認可の増加により、2022年に低分子分野が最大のシェアを占める

- 低投資や高い製造効率など、アウトソース製造に伴う様々な利点により、2022年にアウトソース部門が最大の市場シェアを占めた

- 剤形別では、2022年に錠剤が米国・欧州の医薬品製造業界を支配し、スプレー分野が急成長すると予想される

- 売れ筋の製剤が経口剤として入手しやすく、経口製剤の需要が高いことから、2022年に経口分野が最大となった

- 治療領域別では、がん分野が最大の収益シェアを占めています。一方、呼吸器疾患分野は飛躍的な成長が見込まれています。

- 欧州は、良好な政府政策と継続的な研究活動により、予測期間中に最も速い成長を示すと予想される



ページTOPに戻る


目次

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Competitive Insights
Chapter 3 U.S. & Europe Pharmaceutical Manufacturing Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Rise in pharmaceutical R&D spending
3.2.1.2 Advancements in pharmaceutical manufacturing technologies
3.2.1.3 Increasing geriatric population and incidence of chronic disorders
3.2.2 Market restraint analysis
3.2.2.1 Challenges pertaining to pharma supply chain
3.2.2.2 Pricing pressures on pharmaceutical companies
3.3 Penetration & Growth Prospect Mapping
3.4 U.S. & Europe Pharmaceutical Manufacturing Market: Market Analysis Tools
3.4.1 Industry analysis - Porter’s
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
Chapter 4 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Product Type, 2018 - 2030 (USD Billion)
4.1 Definition and Scope
4.2 Product Type Market Share Analysis, 2022 & 2030
4.3 Segment Dashboard
4.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Product Type, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.5.1 Small Molecule
4.5.1.1 Small molecule market estimates and forecast, 2018 - 2030 (USD Billion)
4.5.2 Large Molecule
4.5.2.1 Large molecule market estimates and forecast, 2018 - 2030 (USD Billion)
4.5.2.1.1 Monoclonal Antibodies
4.5.2.1.1.1 Monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
4.5.2.1.2 Vaccines
4.5.2.1.2.1 Vaccines market estimates and forecast, 2018 - 2030 (USD Billion)
4.5.2.1.3 Cell & Gene Therapy
4.5.2.1.3.1 Cell & Gene therapy market estimates and forecast, 2018 - 2030 (USD Billion)
4.5.2.1.4 Others
4.5.2.1.4.1 Others molecule market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 5 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Drug Development Type 2018 - 2030 (USD Billion)
5.1 Definition and Scope
5.2 Drug Development Type Market Share Analysis, 2022 & 2030
5.3 Segment Dashboard
5.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Drug Development Type, 2018 to 2030
5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.5.1 Outsource
5.5.1.1 Outsource market estimates and forecast, 2018 - 2030 (USD Billion)
5.5.2 In - house
5.5.2.1 In - house market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 6 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Route of Administration, 2018 - 2030 (USD Billion)
6.1 Definition and Scope
6.2 Route of Administration Market Share Analysis, 2022 & 2030
6.3 Segment Dashboard
6.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Route of Administration, 2018 to 2030
6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.5.1 Oral
6.5.1.1 Oral market estimates and forecast, 2018 - 2030 (USD Billion)
6.5.2 Topical
6.5.2.1 Topical market estimates and forecast, 2018 - 2030 (USD Billion)
6.5.3 Parenterals
6.5.3.1 Parenterals market estimates and forecast, 2018 - 2030 (USD Billion)
6.5.4 Inhalations
6.5.4.1 Inhalations market estimates and forecast, 2018 - 2030 (USD Billion)
6.5.5 Others
6.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 7 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Formulation, 2018 - 2030 (USD Billion)
7.1 Definition and Scope
7.2 Formulation Market Share Analysis, 2022 & 2030
7.3 Segment Dashboard
7.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Formulation, 2018 to 2030
7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
7.5.1 Tablets
7.5.1.1 Tablets market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.2 Capsules
7.5.2.1 Capsules market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.3 Injectables
7.5.3.1 Injectables market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.4 Sprays
7.5.4.1 Sprays market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.5 Suspensions
7.5.5.1 Suspensions market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.6 Powders
7.5.6.1 Powders market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.7 Others
7.5.7.1 Others market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 8 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Therapy Area, 2018 - 2030 (USD Billion)
8.1 Definition and Scope
8.2 Therapy Area Market Share Analysis, 2022 & 2030
8.3 Segment Dashboard
8.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Therapy Area, 2018 to 2030
8.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
8.5.1 Cardiovascular Diseases
8.5.1.1 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Billion)
8.5.2 Pain
8.5.2.1 Pain market estimates and forecast, 2018 - 2030 (USD Billion)
8.5.3 Diabetes
8.5.3.1 Diabetes market estimates and forecast, 2018 - 2030 (USD Billion)
8.5.4 Cancer
8.5.4.1 Cancer market estimates and forecast, 2018 - 2030 (USD Billion)
8.5.5 Respiratory Diseases
8.5.5.1 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Billion)
8.5.6 Others
8.5.6.1 Others market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 9 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Prescription Requirements, 2018 - 2030 (USD Billion)
9.1 Definition and Scope
9.2 Prescription Requirements Market Share Analysis, 2022 & 2030
9.3 Segment Dashboard
9.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Prescription Requirements, 2018 to 2030
9.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
9.5.1 Prescription Medicines
9.5.1.1 Prescription medicines market estimates and forecast, 2018 - 2030 (USD Billion)
9.5.2 Over - the - counter (OTC) Medicines
9.5.2.1 Over - the - counter (OTC) medicines market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 10 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Age Type, 2018 - 2030 (USD Billion)
10.1 Definition and Scope
10.2 Age Type Market Share Analysis, 2022 & 2030
10.3 Segment Dashboard
10.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Age Type, 2018 to 2030
10.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
10.5.1 Children & Adolescents
10.5.1.1 Children & adolescents market estimates and forecast, 2018 - 2030 (USD Billion)
10.5.2 Adults
10.5.2.1 Adults market estimates and forecast, 2018 - 2030 (USD Billion)
10.5.3 Geriatric
10.5.3.1 Geriatric market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 11 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Sales Channel, 2018 - 2030 (USD Billion)
11.1 Definition and Scope
11.2 Sales Channel Market Share Analysis, 2022 & 2030
11.3 Segment Dashboard
11.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Sales Channel, 2018 to 2030
11.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
11.5.1 Retail
11.5.1.1 Retail market estimates and forecast, 2018 - 2030 (USD Billion)
11.5.2 Non - retail
11.5.2.1 Non - retail market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 12 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Region, 2018 - 2030 (USD Billion)
12.1 Definition & Scope
12.2 Regional Market Share Analysis, 2022 & 2030
12.3 Regional Market Dashboard
12.4 Regional Market Snapshot
12.5 SWOT Analysis
12.5.1 U.S.
12.5.2 Europe
12.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
12.6.1 U.S.
12.6.1.1 Key Country Dynamics
12.6.1.2 Competitive Scenario
12.6.1.3 Regulatory Framework
12.6.1.4 Reimbursement Scenario
12.6.1.5 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2 Europe
12.6.2.1 Europe pharmaceutical manufacturing market, 2018 - 2030 (USD Billion)
12.6.2.2 U.K.
12.6.2.2.1 Key Country Dynamics
12.6.2.2.2 Competitive Scenario
12.6.2.2.3 Regulatory Framework
12.6.2.2.4 Reimbursement Scenario
12.6.2.2.5 U.K. pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.3 Germany
12.6.2.3.1 Key Country Dynamics
12.6.2.3.2 Competitive Scenario
12.6.2.3.3 Regulatory Framework
12.6.2.3.4 Reimbursement Scenario
12.6.2.3.5 Germany pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.4 Spain
12.6.2.4.1 Key Country Dynamics
12.6.2.4.2 Competitive Scenario
12.6.2.4.3 Regulatory Framework
12.6.2.4.4 Reimbursement Scenario
12.6.2.4.5 Spain pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.5 France
12.6.2.5.1 Key Country Dynamics
12.6.2.5.2 Competitive Scenario
12.6.2.5.3 Regulatory Framework
12.6.2.5.4 Reimbursement Scenario
12.6.2.5.5 France pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.6 Italy
12.6.2.6.1 Key Country Dynamics
12.6.2.6.2 Competitive Scenario
12.6.2.6.3 Regulatory Framework
12.6.2.6.4 Reimbursement Scenario
12.6.2.6.5 Italy pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.7 Denmark
12.6.2.7.1 Key Country Dynamics
12.6.2.7.2 Competitive Scenario
12.6.2.7.3 Regulatory Framework
12.6.2.7.4 Reimbursement Scenario
12.6.2.7.5 Denmark pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.8 Sweden
12.6.2.8.1 Key Country Dynamics
12.6.2.8.2 Competitive Scenario
12.6.2.8.3 Regulatory Framework
12.6.2.8.4 Reimbursement Scenario
12.6.2.8.5 Sweden pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.9 Norway
12.6.2.9.1 Key Country Dynamics
12.6.2.9.2 Competitive Scenario
12.6.2.9.3 Regulatory Framework
12.6.2.9.4 Reimbursement Scenario
12.6.2.9.5 Norway pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 13 U.S. & Europe Pharmaceutical Manufacturing Market - Competitive Analysis
13.1 Recent Developments & Impact Analysis, by Key Market Participants
13.1.1 Ansoff matrix
13.1.2 Heat map analysis
13.1.3 Major Deals and Strategic Alliances Analysis
13.1.3.1 Joint Ventures
13.1.3.2 Licensing Agreements
13.1.3.3 Product Launches
13.1.3.4 Conferences and Campaigns
13.2 Company Categorization
13.2.1 Innovators
13.2.2 Market Leaders
13.3 Vendor Landscape
13.3.1 List of key distributors and channel partners
13.3.2 Key customers
13.4 Public Companies
13.4.1 Competitive Dashboard Analysis
13.4.1.1 Market Differentiators
13.5 Private Companies
13.5.1 List of key emerging companies
13.6 Company Profiles
13.6.1 AbbVie Inc
13.6.1.1 Company overview
13.6.1.2 Financial performance
13.6.1.3 Product benchmarking
13.6.1.4 Strategic Initiatives
13.6.2 Pfizer Inc.
13.6.2.1 Company overview
13.6.2.2 Financial performance
13.6.2.3 Product benchmarking
13.6.2.4 Strategic Initiatives
13.6.3 Novartis AG
13.6.3.1 Company overview
13.6.3.2 Financial performance
13.6.3.3 Product benchmarking
13.6.3.4 Strategic Initiatives
13.6.4 F. Hoffmann - La Roche Ltd
13.6.4.1 Company overview
13.6.4.2 Financial performance
13.6.4.3 Product benchmarking
13.6.4.4 Strategic Initiatives
13.6.5 Merck & Co., Inc.
13.6.5.1 Company overview
13.6.5.2 Financial performance
13.6.5.3 Product benchmarking
13.6.5.4 Strategic Initiatives
13.6.6 Johnson & Johnson Services, Inc.
13.6.6.1 Company overview
13.6.6.2 Financial performance
13.6.6.3 Product benchmarking
13.6.6.4 Strategic Initiatives
13.6.7 GSK plc
13.6.7.1 Company overview
13.6.7.2 Financial performance
13.6.7.3 Product benchmarking
13.6.7.4 Strategic initiatives
13.6.8 Sanofi
13.6.8.1 Company overview
13.6.8.2 Financial performance
13.6.8.3 Product benchmarking
13.6.8.4 Strategic initiatives
13.6.9 Lonza
13.6.9.1 Company overview
13.6.9.2 Financial performance
13.6.9.3 Product benchmarking
13.6.9.4 Strategic initiatives
13.6.10 Samsung Biologics
13.6.10.1 Company overview
13.6.10.2 Financial performance
13.6.10.3 Product benchmarking
13.6.10.4 Strategic initiatives
13.6.11 Lilly
13.6.11.1 Company overview
13.6.11.2 Financial performance
13.6.11.3 Product benchmarking
13.6.11.4 Strategic initiatives

 

ページTOPに戻る


 

Summary

U.S. And Europe Pharmaceutical Manufacturing Market Growth & Trends

The U.S. and Europe pharmaceutical manufacturing market size is expected to reach USD 641.22 billion by 2030 and is expected to expand at 6.81% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. The presence of supportive regulatory legislation, patentability norms, high investments in the pharmaceutical industry, and increasing healthcare expenditure remain key drivers of growth. In addition, the rising trend of third-party production across the pharmaceutical sector along with the increased emphasis on cost-cutting approaches are likely to provide lucrative growth opportunities.

A continuous increase in the number of clinical trials of pharmaceutical products is expected to create numerous opportunities for market growth in the coming years. According to ClinicalTrials.gov, as of January 2023, a total of 137,145 ongoing clinical studies were registered in the U.S., which accounts for 31% of overall clinical trials. This increase in the number of clinical studies indicates the growth of the pharmaceutical industry, which is likely to create new avenues for market stakeholders.

Moreover, the majority of pharmaceutical manufacturers have shifted their preference toward continuous production approaches to overcome medicines shortages, reduces production cost, and improve manufacturing efficiencies. For instance, in January 2021, CONTINUUS Pharmaceuticals Inc. announced a receipt of USD 69.3 million U.S. government contract to speed up country-level production of three essential medicines to treat severely ill patients. Moreover, this contract helped the company to enable cost-efficient production to facilitate the delivery of high-quality and affordable therapeutics to patients.

Government initiatives to establish domestic pharmaceutical manufacturing sites are one of the determinants of pharmaceutical manufacturing market growth. For instance, in April 2022, CureVac and GSK plc entered into a partnership to be part of the German Pandemic contingency plan to increase mRNA production capacity and the government will receive access to CureVac’s production capacity until 2029.

The UK government is taking action to establish local manufacturing through Medicines Manufacturing Innovation Centre. Under this program, drug makers, academic institutions, healthcare providers, and regulatory bodies are expected to combine their resources at the facility to test and enhance new technologies, including autonomous production.

Furthermore, the organic and inorganic developments undertaken by pharmaceutical companies to strengthen their business avenues are anticipated to support market expansion. For instance, in October 2021, Samsung Biologics and Enzolytics, Inc. signed a development & manufacturing agreement for Anti-SARS-CoV-2 Monoclonal Antibody and Anti-HIV therapies. Similarly, in February 2021, WuXi STA purchased Bristol Myers Squibb’s manufacturing unit in Switzerland. This expansion will further enhance its existing capabilities.

U.S. And Europe Pharmaceutical Manufacturing Market Highlights

• The small molecule segment held the largest share of the market in 2022, owing to the high consumption rate of small molecules and increasing product approvals

• The outsource segment accounted for the largest market share in 2022 due to various benefits associated with outsource manufacturing such as low investment and high manufacturing efficiency

• Based on formulation, the tablets dominated the U.S. & Europe pharmaceutical manufacturing industry in 2022, whereas the sprays segment is anticipated to be the fastest-growing segment

• The oral segment was the largest in 2022 owing to the high availability of top-selling preparations as an oral dosage form and a high demand for oral formulations

• Based on the therapy area, the cancer segment held the largest revenue share of the market. Whereas the respiratory diseases segment is anticipated to grow at an exponential growth rate

• Europe is expected to exhibit the fastest growth during the forecast period due to favorable government policies and ongoing research activities



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Competitive Insights
Chapter 3 U.S. & Europe Pharmaceutical Manufacturing Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Rise in pharmaceutical R&D spending
3.2.1.2 Advancements in pharmaceutical manufacturing technologies
3.2.1.3 Increasing geriatric population and incidence of chronic disorders
3.2.2 Market restraint analysis
3.2.2.1 Challenges pertaining to pharma supply chain
3.2.2.2 Pricing pressures on pharmaceutical companies
3.3 Penetration & Growth Prospect Mapping
3.4 U.S. & Europe Pharmaceutical Manufacturing Market: Market Analysis Tools
3.4.1 Industry analysis - Porter’s
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
Chapter 4 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Product Type, 2018 - 2030 (USD Billion)
4.1 Definition and Scope
4.2 Product Type Market Share Analysis, 2022 & 2030
4.3 Segment Dashboard
4.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Product Type, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.5.1 Small Molecule
4.5.1.1 Small molecule market estimates and forecast, 2018 - 2030 (USD Billion)
4.5.2 Large Molecule
4.5.2.1 Large molecule market estimates and forecast, 2018 - 2030 (USD Billion)
4.5.2.1.1 Monoclonal Antibodies
4.5.2.1.1.1 Monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
4.5.2.1.2 Vaccines
4.5.2.1.2.1 Vaccines market estimates and forecast, 2018 - 2030 (USD Billion)
4.5.2.1.3 Cell & Gene Therapy
4.5.2.1.3.1 Cell & Gene therapy market estimates and forecast, 2018 - 2030 (USD Billion)
4.5.2.1.4 Others
4.5.2.1.4.1 Others molecule market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 5 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Drug Development Type 2018 - 2030 (USD Billion)
5.1 Definition and Scope
5.2 Drug Development Type Market Share Analysis, 2022 & 2030
5.3 Segment Dashboard
5.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Drug Development Type, 2018 to 2030
5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.5.1 Outsource
5.5.1.1 Outsource market estimates and forecast, 2018 - 2030 (USD Billion)
5.5.2 In - house
5.5.2.1 In - house market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 6 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Route of Administration, 2018 - 2030 (USD Billion)
6.1 Definition and Scope
6.2 Route of Administration Market Share Analysis, 2022 & 2030
6.3 Segment Dashboard
6.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Route of Administration, 2018 to 2030
6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.5.1 Oral
6.5.1.1 Oral market estimates and forecast, 2018 - 2030 (USD Billion)
6.5.2 Topical
6.5.2.1 Topical market estimates and forecast, 2018 - 2030 (USD Billion)
6.5.3 Parenterals
6.5.3.1 Parenterals market estimates and forecast, 2018 - 2030 (USD Billion)
6.5.4 Inhalations
6.5.4.1 Inhalations market estimates and forecast, 2018 - 2030 (USD Billion)
6.5.5 Others
6.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 7 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Formulation, 2018 - 2030 (USD Billion)
7.1 Definition and Scope
7.2 Formulation Market Share Analysis, 2022 & 2030
7.3 Segment Dashboard
7.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Formulation, 2018 to 2030
7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
7.5.1 Tablets
7.5.1.1 Tablets market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.2 Capsules
7.5.2.1 Capsules market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.3 Injectables
7.5.3.1 Injectables market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.4 Sprays
7.5.4.1 Sprays market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.5 Suspensions
7.5.5.1 Suspensions market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.6 Powders
7.5.6.1 Powders market estimates and forecast, 2018 - 2030 (USD Billion)
7.5.7 Others
7.5.7.1 Others market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 8 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Therapy Area, 2018 - 2030 (USD Billion)
8.1 Definition and Scope
8.2 Therapy Area Market Share Analysis, 2022 & 2030
8.3 Segment Dashboard
8.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Therapy Area, 2018 to 2030
8.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
8.5.1 Cardiovascular Diseases
8.5.1.1 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Billion)
8.5.2 Pain
8.5.2.1 Pain market estimates and forecast, 2018 - 2030 (USD Billion)
8.5.3 Diabetes
8.5.3.1 Diabetes market estimates and forecast, 2018 - 2030 (USD Billion)
8.5.4 Cancer
8.5.4.1 Cancer market estimates and forecast, 2018 - 2030 (USD Billion)
8.5.5 Respiratory Diseases
8.5.5.1 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Billion)
8.5.6 Others
8.5.6.1 Others market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 9 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Prescription Requirements, 2018 - 2030 (USD Billion)
9.1 Definition and Scope
9.2 Prescription Requirements Market Share Analysis, 2022 & 2030
9.3 Segment Dashboard
9.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Prescription Requirements, 2018 to 2030
9.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
9.5.1 Prescription Medicines
9.5.1.1 Prescription medicines market estimates and forecast, 2018 - 2030 (USD Billion)
9.5.2 Over - the - counter (OTC) Medicines
9.5.2.1 Over - the - counter (OTC) medicines market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 10 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Age Type, 2018 - 2030 (USD Billion)
10.1 Definition and Scope
10.2 Age Type Market Share Analysis, 2022 & 2030
10.3 Segment Dashboard
10.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Age Type, 2018 to 2030
10.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
10.5.1 Children & Adolescents
10.5.1.1 Children & adolescents market estimates and forecast, 2018 - 2030 (USD Billion)
10.5.2 Adults
10.5.2.1 Adults market estimates and forecast, 2018 - 2030 (USD Billion)
10.5.3 Geriatric
10.5.3.1 Geriatric market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 11 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Sales Channel, 2018 - 2030 (USD Billion)
11.1 Definition and Scope
11.2 Sales Channel Market Share Analysis, 2022 & 2030
11.3 Segment Dashboard
11.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Sales Channel, 2018 to 2030
11.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
11.5.1 Retail
11.5.1.1 Retail market estimates and forecast, 2018 - 2030 (USD Billion)
11.5.2 Non - retail
11.5.2.1 Non - retail market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 12 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Region, 2018 - 2030 (USD Billion)
12.1 Definition & Scope
12.2 Regional Market Share Analysis, 2022 & 2030
12.3 Regional Market Dashboard
12.4 Regional Market Snapshot
12.5 SWOT Analysis
12.5.1 U.S.
12.5.2 Europe
12.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
12.6.1 U.S.
12.6.1.1 Key Country Dynamics
12.6.1.2 Competitive Scenario
12.6.1.3 Regulatory Framework
12.6.1.4 Reimbursement Scenario
12.6.1.5 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2 Europe
12.6.2.1 Europe pharmaceutical manufacturing market, 2018 - 2030 (USD Billion)
12.6.2.2 U.K.
12.6.2.2.1 Key Country Dynamics
12.6.2.2.2 Competitive Scenario
12.6.2.2.3 Regulatory Framework
12.6.2.2.4 Reimbursement Scenario
12.6.2.2.5 U.K. pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.3 Germany
12.6.2.3.1 Key Country Dynamics
12.6.2.3.2 Competitive Scenario
12.6.2.3.3 Regulatory Framework
12.6.2.3.4 Reimbursement Scenario
12.6.2.3.5 Germany pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.4 Spain
12.6.2.4.1 Key Country Dynamics
12.6.2.4.2 Competitive Scenario
12.6.2.4.3 Regulatory Framework
12.6.2.4.4 Reimbursement Scenario
12.6.2.4.5 Spain pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.5 France
12.6.2.5.1 Key Country Dynamics
12.6.2.5.2 Competitive Scenario
12.6.2.5.3 Regulatory Framework
12.6.2.5.4 Reimbursement Scenario
12.6.2.5.5 France pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.6 Italy
12.6.2.6.1 Key Country Dynamics
12.6.2.6.2 Competitive Scenario
12.6.2.6.3 Regulatory Framework
12.6.2.6.4 Reimbursement Scenario
12.6.2.6.5 Italy pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.7 Denmark
12.6.2.7.1 Key Country Dynamics
12.6.2.7.2 Competitive Scenario
12.6.2.7.3 Regulatory Framework
12.6.2.7.4 Reimbursement Scenario
12.6.2.7.5 Denmark pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.8 Sweden
12.6.2.8.1 Key Country Dynamics
12.6.2.8.2 Competitive Scenario
12.6.2.8.3 Regulatory Framework
12.6.2.8.4 Reimbursement Scenario
12.6.2.8.5 Sweden pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
12.6.2.9 Norway
12.6.2.9.1 Key Country Dynamics
12.6.2.9.2 Competitive Scenario
12.6.2.9.3 Regulatory Framework
12.6.2.9.4 Reimbursement Scenario
12.6.2.9.5 Norway pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 13 U.S. & Europe Pharmaceutical Manufacturing Market - Competitive Analysis
13.1 Recent Developments & Impact Analysis, by Key Market Participants
13.1.1 Ansoff matrix
13.1.2 Heat map analysis
13.1.3 Major Deals and Strategic Alliances Analysis
13.1.3.1 Joint Ventures
13.1.3.2 Licensing Agreements
13.1.3.3 Product Launches
13.1.3.4 Conferences and Campaigns
13.2 Company Categorization
13.2.1 Innovators
13.2.2 Market Leaders
13.3 Vendor Landscape
13.3.1 List of key distributors and channel partners
13.3.2 Key customers
13.4 Public Companies
13.4.1 Competitive Dashboard Analysis
13.4.1.1 Market Differentiators
13.5 Private Companies
13.5.1 List of key emerging companies
13.6 Company Profiles
13.6.1 AbbVie Inc
13.6.1.1 Company overview
13.6.1.2 Financial performance
13.6.1.3 Product benchmarking
13.6.1.4 Strategic Initiatives
13.6.2 Pfizer Inc.
13.6.2.1 Company overview
13.6.2.2 Financial performance
13.6.2.3 Product benchmarking
13.6.2.4 Strategic Initiatives
13.6.3 Novartis AG
13.6.3.1 Company overview
13.6.3.2 Financial performance
13.6.3.3 Product benchmarking
13.6.3.4 Strategic Initiatives
13.6.4 F. Hoffmann - La Roche Ltd
13.6.4.1 Company overview
13.6.4.2 Financial performance
13.6.4.3 Product benchmarking
13.6.4.4 Strategic Initiatives
13.6.5 Merck & Co., Inc.
13.6.5.1 Company overview
13.6.5.2 Financial performance
13.6.5.3 Product benchmarking
13.6.5.4 Strategic Initiatives
13.6.6 Johnson & Johnson Services, Inc.
13.6.6.1 Company overview
13.6.6.2 Financial performance
13.6.6.3 Product benchmarking
13.6.6.4 Strategic Initiatives
13.6.7 GSK plc
13.6.7.1 Company overview
13.6.7.2 Financial performance
13.6.7.3 Product benchmarking
13.6.7.4 Strategic initiatives
13.6.8 Sanofi
13.6.8.1 Company overview
13.6.8.2 Financial performance
13.6.8.3 Product benchmarking
13.6.8.4 Strategic initiatives
13.6.9 Lonza
13.6.9.1 Company overview
13.6.9.2 Financial performance
13.6.9.3 Product benchmarking
13.6.9.4 Strategic initiatives
13.6.10 Samsung Biologics
13.6.10.1 Company overview
13.6.10.2 Financial performance
13.6.10.3 Product benchmarking
13.6.10.4 Strategic initiatives
13.6.11 Lilly
13.6.11.1 Company overview
13.6.11.2 Financial performance
13.6.11.3 Product benchmarking
13.6.11.4 Strategic initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/10/04 10:27

147.72 円

163.39 円

196.69 円

ページTOPに戻る